In rehabilitation clinics across Australia, people with cerebral palsy are strapping into robotic exoskeletons—wearable devices that support their limbs and help them move with greater strength, speed, and control. It's a moment that signals a genuine shift in how therapists can support the 50 million people worldwide living with the most common childhood disability.
Cerebral palsy affects a person's ability to move and control their muscles, often resulting in stiffness, weakness, and abnormal movements. Many people also experience related neurological challenges like epilepsy or visual impairment. For decades, physiotherapy has been the standard treatment—treadmill training, strength work, and task-specific practice like learning to get in and out of a car. But a newer tool is proving itself worthy of attention: lower-limb robotic exoskeletons, wearable devices that support posture and movement from the outside.
The technology itself has come a long way. The first exoskeletons designed to help people walk emerged in the 1960s as clunky, laboratory-bound contraptions. Over six decades of refinement, they've become streamlined enough that several have now received approval from Australia's Therapeutic Goods Administration. The latest generation includes devices that can be used overground—not tethered to treadmills—which means users can move through real environments and interact with their surroundings naturally. Some even show promise as longer-term assistive devices for everyday life.
A new systematic review published in Disability and Rehabilitation examined whether these exoskeletons could meaningfully help people with cerebral palsy specifically. Researchers analyzed 21 studies involving 241 people with cerebral palsy, averaging nine years old, and compared outcomes between robotic-assisted therapy and conventional physiotherapy. The findings are encouraging.
Robotic rehabilitation outperformed conventional therapy in four critical areas: walking speed, walking endurance, balance, and high-level mobility such as running and jumping. These aren't marginal improvements—they represent meaningful gains in the physical abilities that matter most to people's daily independence and participation. For other outcomes measured in the studies, the evidence was either insufficient to draw firm conclusions or showed inconsistent results.
The research also found that skin irritation was occasionally reported, but never severe enough to prevent anyone from continuing to use the device. Where user experiences were documented—though this was notably absent from most studies—people reported generally positive reactions to the technology.
The timing of this evidence is particularly significant. Australia's National Disability Insurance Scheme, the country's peak disability funding body, has asked an advisory committee to review supports for people with disability, including robot-assisted gait training. That review will determine whether and how this technology gets funded through public disability support systems, potentially opening access for thousands of Australians.
What remains unclear is how these benefits hold up over time, whether they transfer to real-world activities beyond the clinic, and how the technology might be refined to work even better for younger children or those with more severe mobility challenges. But the foundation is solid: exoskeletons are no longer theoretical tools for cerebral palsy. They're here, they're working, and the question now is how quickly the world will ensure they reach the people who need them most.